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We examined the utility of DNA methylation proﬁles at the CpG island of SLC6A4 (DMS) as a diagnostic
biomarker for major depression (MD). In addition, the relationship between DMS and the serotonin
transporter gene-linked polymorphic region (5-HTTLPR) allele, the severity of symptoms, number of
early adversities, and therapeutic responses to antidepressants were examined. Genomic DNA was
extracted from peripheral blood of Japanese healthy controls and patients with MD before and after
treatment. DMS was analyzed using a MassARRAY Compact System. The severity of depression was
evaluated using the Hamilton Rating Scale for Depression, and early adversity was evaluated using the
Early Trauma Inventory. We were unable to distinguish between and healthy controls, or between un-
medicated patients and medicated patients using DMS. The 5-HTTLPR allele had no signiﬁcant effect on
DMS. The methylation rates for several CpGs differed signiﬁcantly after treatment. Notably, the
methylation rate of CpG 3 in patients with better therapeutic responses was signiﬁcantly higher than that
in patients with poorer responses. Although further studies examining the function of speciﬁc CpG units
of SLC6A4 are required, these results suggest that the pre-treatment methylation rate of SLC6A4 is
associated with therapeutic responses to antidepressants in unmedicated patients with MD.
 2014 Elsevier Ltd. All rights reserved.1. Introduction
Major depression (MD) is a common illness worldwide and was
the second-leading contributor to global disease burden in 2010
(Vos et al., 2012). Since long-lasting emotional and psychomotor
disturbances due to MD can induce functional difﬁculties at work,
school, or home, MD is predicted to become the second-leading
cause of disability-adjusted life years in 2020 based on thent of Neuropsychiatry, Kochi
o, Nankoku, Kochi, Japan.
obu).
y, Keio University School ofsystematic analyses of population health data (Murray and Lopez,
1997). In addition, MD is a leading cause of suicide and is respon-
sible for 1 million suicide-related deaths every year (WHO, 2012).
In this context, early diagnosis and intervention are necessary to
prevent worsening of MD and MD-related suicide attempts. How-
ever, the diagnostic system for MD, which relies on subjective
assessment of patient symptoms using, for example, the Diagnostic
and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV)
or the International Classiﬁcation of Diseases Tenth Edition (ICD-
10) rather than an objective laboratory test, may be associated with
misdiagnoses, poor outcomes in the treatment of MD, and devel-
opment of refractory depression.
To establish objective diagnostic biomarkers for MD, numerous
approaches have been undertaken. For example, Carroll et al.
(1981) and Carroll (1982) proposed dexamethasone suppression
S. Okada et al. / Journal of Psychiatric Research 53 (2014) 47e5348test (DST) results as a biomarker for the diagnosis of melancholia
based on dysregulation of the hypothalamoepituitaryeadrenal
(HPA) axis in MD, but a major drawback of DST was its modest
sensitivity. Subsequently, a reﬁned laboratory test, the combined
dexamethasone/corticotrophin-releasing hormone (DEX/CRH) test,
was developed (Heuser et al., 1994), although the sensitivity for
detection of MD was only 80% at best (Mossner et al., 2007).
We recently proposed that the methylation proﬁle of the pro-
moter region of exon I of the brain-derived neurotrophic factor
(BDNF) gene could serve as a valuable diagnostic biomarker for MD
(Fuchikami et al., 2011). It is well known that the concordance rate
for MD in monozygotic twins is almost 40% (Fu et al., 2002;
McGufﬁn et al., 1996; Sullivan et al., 2000). The heritability of MD
is lower than that of bipolar disorder or schizophrenia (Goodwin
and Jamison, 2007; Moldin and Gottesman, 1997). These epidemi-
ological studies suggest that geneeenvironment interactions play a
pivotal role in the etiology of MD. With regard to this interaction,
growing evidence indicates that the regulation of DNA methylation
in response to environmental stimuli plays an important role in the
development of stress vulnerability, predisposing to MD under
stressful situations (McGowan et al., 2009; Weaver et al., 2004;
Zhang et al., 2013). Thus, it is plausible that epigenetic factors
could be used for the development of a more sophisticated diag-
nosis system for MD.
The serotonin transporter (5-HTT) is a major target of anti-
depressants and the activity of 5-HTT is inhibited by different
types of antidepressants. In vivo neuroimaging and postmortem
histochemical studies have shown decreased 5-HTT binding
density mainly in the prefrontal cortex of patients with MD
(Stockmeier, 2003). Whereas a recent in vivo neuroimaging study
using positron emission tomography (PET) demonstrated
increased 5-HTT binding in the thalamus, insula, and striatum of
patients with MD (Cannon et al., 2007), another PET study re-
ported lower 5-HTT binding in the midbrain of patients with MD,
particularly those who were unmedicated (Parsey et al., 2006).
Based on these ﬁndings, it is conceivable that altered 5-HTT
function in the brain plays an important role in the pathophysi-
ology of depression.
Furthermore, it is well known that the short (s) allele of the 5-
HTT gene-linked polymorphic region (5-HTTLPR: 43-bp deletion
or insertion in the promoter of exon I) is associated with anxiety-
related personality traits (Lesch et al., 1996), and that this poly-
morphism is associated with decreased expression of the 5-HTT
gene in the 5-HTTLPR s allele (Bradley et al., 2005). The 5-HTTLPR
s allele has been reported to be associated with an increased risk
of developing depression under stress (Karg et al., 2011).
A recent meta-analysis revealed a signiﬁcant association be-
tween 5-HTTLPR and the clinical response to selective serotonin
reuptake inhibitor (SSRI) treatment in terms of both the remission
rate and response rate in depressed patients. This suggests that 5-
HTTLPR could be a predictor of the response to SSRIs (Serretti et al.,
2007). Together, these observations indicate that individual differ-
ences in the transcriptional activity of 5-HTT might be involved in
the pathophysiology of MD and the response to antidepressant
treatment.
With regard to the regulation of 5-HTT expression, the
methylation rate of the CpG island at the 50 region of the SLC6A4
gene have been reported to be associated with the levels of 5-HTT
mRNA in human lymphoblast cells (Philibert et al., 2007). In addi-
tion, Wang and associates (Wang et al., 2012) reported that in vitro
methylation in the promoter of exon I of the SLC6A4 gene in a
luciferase-reporter construct suppressed its transcriptional activity.
Furthermore, the possibility of a joint effect of 5-HTT methylation
and 5-HTTLPR s allele carriage on the risk for depression was re-
ported recently (Olsson et al., 2010). These ﬁndings suggest that themethylation status of the promoter of exon I of the SLC6A4 gene
alters transcription of the SLC6A4 gene, and subsequently leads to
the occurrence of MD.
It has also been reported that early adversity is associated with
increased prevalence, earlier onset (Widom et al., 2007) or severity
of symptoms, treatment resistance of MD (Tunnard et al., 2013;
Widom et al., 2007), and elevated DNA methylation across the
SLC6A4 gene promoter in subjects without MD as well as in those
without psychiatric disorders (Beach et al., 2010, 2011). Further-
more, increased DNA methylation of the SLC6A4 gene has been
reported to be associated with bullying victimization in childhood
(Ouellet-Morin et al., 2013).
In the present study, we assessed the degree of symptoms and
early adversity of patients with MD, analyzed DNA methylation
rates of the CpG island in the promoter of exon I of the SLC6A4
gene (DMR), and conducted genotyping of 5-HTTLPR using
genomic DNA from the peripheral blood of patients with MD or
healthy controls.
First, we examined whether the proﬁle of the SLC6A4 gene was
an appropriate diagnostic biomarker for MD. Next, we analyzed
the effect of genotype on DMR, the relationship between DMR and
the severity of symptoms, and the association between DMR and
the number of early adversities. Finally, the effect of antidepres-
sant treatment on DMR and the relationship between DMR and
response rates was analyzed by comparing data sets from patients
with MD before and after antidepressant treatment to evaluate
the potential of DMR as a predictor of the treatment response.2. Materials and methods
2.1. Subjects
Fifty patients with MD and 50 healthy controls participated in
this study. Demographic characteristics of the participants are
shown in Table 1. All participants were Japanese. All patients were
diagnosed by trained psychiatrists according to DSM-IV criteria, on
the basis of unstructured interviews, information from medical
records, and the use of a structured clinical interview (the Japanese
version of the Mini-International Neuropsychiatric Interview) by a
research psychiatrist. The criteria for the selection of samples in
this study was as follows: (1) median age (21e62 years old), (2)
distribution of sex was almost equal among groups, (3) severity of
symptoms were moderate so as to be able to give written informed
consent, (4) all patients did not have treatment history or previous
depressed episodes. The severity of depressionwas evaluated using
the Hamilton Rating Scale for Depression (HAM-D; Hamilton, 1967;
Cusin et al., 2009) and early adversity was evaluated using the Early
Trauma Inventory Self Report-Short Form (ETISR-SF; Bremner et al.,
2000, 2007).
None of the patients had current or past diagnoses of
substance-related disorders or physical diagnoses. Healthy con-
trols were recruited by advertisement. They had no current or past
psychiatric or physical diagnoses, and they had no ﬁrst-degree
relatives with MD. Blood samples were collected at Hiroshima
University Hospital, Hokkaido University Hospital, Oita University
Hospital and Showa University Hospital. Medical treatment was
initiated in 50 patients; 40 patients were available for a follow-up
interview 6 weeks later, at which time additional blood samples
were collected.
This study was approved by the respective ethics committees of
Hiroshima University School of Medicine, Hokkaido University
School of Medicine, Oita University School of Medicine, and Showa
University School of Medicine. All subjects received a description of
the study and gave written informed consent.
Table 1
Demographic characteristics of subjects.
Group Age (years)
(mean  S.D.)
Genotype HAM-D score (mean  S.D.) ETI score
(mean  S.D.)
IR (%)
(mean  S.D.)
Before After 6 weeks
Control (N ¼ 50, 27M/23F) 40.3  10.5 LL: 2, SL: 16, SS: 32
Major depression (N ¼ 50, 27M/23F) 40.3  10.3 SL: 16, SS: 34 20.6  4.8 8.1  6.6 5.0  3.8 60.2  31.3
M: males, F: females, ETI : Early Trauma Inventory, IR : improvement ratio.
HAM-D: Hamilton Rating Scale for Depression.
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methylation analysis
We chose the CpG island of the SLC6A4 gene as a target for
analysis. The target region around the SLC6A4 gene was selected
based on a previous report (Olsson et al., 2010). The sequence of the
CpG island was identiﬁed using the UCSC genome database (http://
genome.ucsc.edu/) (chr 17: 28562388e28563186). PCR primers
were designed using Epidesigner software (http://www.
epidesigner.com/). The schema for the target region used for
analysis and the primers used for PCR are shown in Fig. 1.
2.3. Genotyping to generate S- and L-fragments
The sequence of 5-HTTLPR was identiﬁed using the UCSC
genome database (chr 17: 28564123e28564473) (Fig. 1). PCR
primers were designed using Primer 3 software (http://frodo.wi.
mit.edu/primer3/input.htm). PCR was performed in a total vol-
ume of 5 mL solution containing 10 ng DNA, 2  Gﬂex PCR Buffer,
1 mM MgCl2, 200 mM dNTPs, 0.2 mM of each primer, and 0.125 U of
Tks Gﬂex DNA polymerase (Takara, Tokyo, Japan) for 30 cycles
(98 C for 10 s, 60 C for 15 s, and 68 C for 30 s). The PCR products
were then analyzed by 2% agarose gel stained with ethidium bro-
mide. The distributions of genotypes in controls and patients with
MD were in HardyeWeinberg equilibrium (Healthy controls:
c2 ¼ 0; Patients: c2 ¼ 1.84) (Table 1).
2.4. DNA methylation analysis by MassARRAY
All samples were collected between 11:00 AM and 1:00 PM,
prior to the participants’ lunch. Blood samples (5 mL) were
collected and placed in vacuum tubes containing heparin sodium
and stored at 80 C. Genomic DNA was isolated using DNeasy
Blood and Tissue Kits (Qiagen, Hilden, Germany). Genomic DNA
(1 mg) was converted with sodium bisulﬁte using EZ DNA methyl-
ation kits (Zymo Research, Orange, CA). The concentration of
bisulﬁte-converted DNA was measured using an ND-1000 spec-
trophotometer (NanoDrop Technologies, Inc., Wilmington, DE,
USA); 10 ng of converted DNAwas used for PCR. PCRwas performed
in a total volume of 5 mL containing 1 mM of each primer, 200 mMFig. 1. Schematic representation of the SLC6A4 gene promoter region. Two primers
covering the SLC6A4 transcription start site, exon I, part of intron I and the CpG island
were used for the DNA methylation study. The target region consists of 862 bp
including 81 CpGs. 5-HTTLPR is located 960 bp upstream of the CpG island.dNTP, 0.2 U HotStar Taq DNA polymerase (Qiagen), 2 mM MgCl2,
and 10  PCR buffer (Sequenom, Inc., San Diego, CA, USA). One of
two primers in the PCR ampliﬁcation of the target regions was
tagged with a T7 promoter sequence: CAGTAATACGACTCACTA-
TAGGGAGAAGGCT. This included a GGG transcription start and an
8-bp insert (AGAAGGCT) on the 50 end. The reaction mixture was
preactivated for 4 min at 95 C. DNA was ampliﬁed for 45 cycles
(95 C for 20 s, 56 C for 30 s and 72 C for 60 s) and the reactionwas
then continued at 72 C for 3 min.
Unincorporated dNTPs were dephosphorylated by adding 1.7 mL
DNase free water and 0.3 U shrimp alkaline phosphatase (SAP)
(Sequenom). The reactionwas incubated at 37 C for 20min and SAP
was inactivated for 5 min at 85 C. Subsequently, PCR products (2 mL)
were incubated for 3 h at 37 C with 5 mL of Transcleave mix
(Sequenom) for concurrent in vitro transcription and base-speciﬁc
cleavage.
The resultant 10- to 20-nL products were spotted onto silicon
matrix-preloaded chips (SpectroCHIP; Sequenom) using a MassAR-
RAY nanodispenser (Sequenom), and analyzed using a MassARRAY
Compact System matrix-assisted laser desorption/ionization-time-
of-ﬂight mass spectrometer (MALDI-TOF-MS) (Sequenom).
The spectra’s methylation ratios were calculated using EpiTYPER
software v1.0 (Sequenom). Triplicate independent analyses from
bisulﬁte-converted DNA samples were undertaken. The method
yielded quantitative results for each of the sequence-deﬁned ana-
lytic units referred to as CpG units. These methods divided 81 CpG
sites in the CpG island into 41 CpG units.
After obtaining the data, initial quality control was performed as
follows. Poor-quality and non-valuable data for the quantitative
methylation of each CpG unit measured by MALDI-TOF-MS were
excluded. Ten CpG units were excluded because their molecular
weights were outside the measurable range. In subsequent ana-
lyses, data for 2 CpG units were excluded as theywere less than 80%
of all samples. Data were available for 29 of 41 CpG units in the CpG
island and for all samples.
2.5. Statistical analysis
For analysis of the DNAmethylation proﬁle, measurements after
QC were combined in a data matrix, which was used in a 2-
dimensional hierarchical clustering analysis with the “R” software
package for statistical computing (available at CRAN, http://cran.r-
project.org/). Hierarchical clustering analyses were performed us-
ing hclust in the R cluster package, with Euclidean metric and
complete linkage. Samples with closer methylation patterns were
closely clustered. The ManneWhitney U test was used to examine
differences in the methylation rates of each CpG unit between
healthy controls and patients. The Wilcoxon signed-rank test was
used to examine differences in the methylation rates of each CpG
unit between patients before and after 6 weeks of antidepressant
treatment. The signiﬁcance of each statistical test by Bonferroni
correction was set at P < 0.0017.
The Spearman rank correlation test was used to examine the
correlation between themethylation rate of each CpG unit and total
HAM-D scores, total ETISR-SF scores, and improvement ratio (IR:
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HAM-D before treatment) in patients. The T-test was used for sub-
sequent analyses of signiﬁcance. Signiﬁcance was set at P < 0.05.
3. Results
3.1. DNA methylation proﬁles in the CpG island of the SLC6A4 gene
among all participants
Two-way hierarchical clustering analysis of DMR was under-
taken to classify samples and CpG units into clusters according to
their similarity, and a dendrogramwas used to visualize the results.
DNAmethylationproﬁles at the CpG island in the SLC6A4 gene of all
subjects are shown in heat map format (Supplemental Fig. 1). At
any height of the dendrogram acquired from clustering analysis, it
was impossible to distinguish between unmedicated patients and
healthy controls (Supplemental Fig. 1).
Next, we compared the methylation rates of each CpG unit be-
tween unmedicated patients and healthy controls. There was no
signiﬁcant difference between unmedicated patients and healthy
controls at any CpG unit (Table 2).
3.2. The inﬂuence of SLC6A4 genotyping for classifying participants
SLC6A4 genotyping analysis demonstrated that 18 healthy
controls had l/l or l/s alleles (an l allele) and 32 healthy controls had
s/s alleles. Similarly, while 16 patients had an l allele, 34 patients
had s/s alleles (Table 1). Two-way hierarchical clustering analysis of
DNA methylation proﬁles could not distinguish samples into any
groups associatedwith diagnosis and/or allele (all participants with
an l allele vs those with s/s alleles, healthy controls with an l alleleTable 2
The DNA methylation rates of each CpG unit at the CpG island of the SLC6A4 gene in he
Control Depression
Rate (%) (mean  S.E.M) Rate (%) (mean  S.E.M)
CpG 1 7.7  0.4 8.4  0.4
CpG 3 5.1  0.2 4.9  0.3
CpG 4 4.1  0.3 4.0  0.3
CpG 10 4.1  0.3 4.0  0.3
CpG 11 24.2  0.7 24.0  0.6
CpG 24,25 5.7  0.2 5.2  0.2
CpG 26,27,28 3.8  0.2 3.7  0.2
CpG 29 4.6  0.4 4.3  0.7
CpG 30 5.5  0.9 5.9  0.3
CpG 31,32 1.6  0.2 4.2  0.2
CpG 33,34,35,36 4.3  0.2 7.3  0.4
CpG 37 6.6  0.2 5.9  0.3
CpG 39,40 4.4  0.1 4.2  0.2
CpG 41,42 7.3  0.4 7.3  0.4
CpG 49,50,51,52 6.0  0.4 5.8  0.3
CpG 55 14.5  0.3 15.0  0.3
CpG 56 1.3  0.2 1.1  0.2
CpG 57,58 20.4  0.5 20.8  0.4
CpG 62 19.9  1.0 20.3  1.0
CpG 65,66 20.4  0.5 20.8  0.4
CpG 67,68 24.1  0.7 23.2  0.8
CpG 70 33.8  1.9 35.2  2.2
CpG 71,72,73 13.8  0.5 14.6  0.4
CpG 74 15.4  0.7 16.1  0.7
CpG 75 49.1  1.8 51.1  1.8
CpG 76 15.9  0.5 16.3  0.7
CpG 78 3.3  0.3 3.7  0.4
CpG 79 9.8  0.8 11.2  0.9
CpG 80,81 32.3  0.7 33.6  0.8
Control (Con): healthy controls, depression (Dep): unmedicated patients with MD, Depr
Statistical analysis: ManneWhitney U test (healthy subjects and unmedicated patients wi
patients with MD).
The mean methylation rate and P-value are shown.
The asterisks (*) behind of scores indicate statistically signiﬁcant P-value. Signiﬁcance wvs those with s/s alleles, or patients with an l allele vs those with s/s
alleles) (Supplemental Fig. 2).
We next compared the methylation rates of each CpG unit
among all participants by two-factor ANOVA using genotypes (l
allele and s/s alleles) and diagnoses (healthy controls and patients)
as ﬁxed factors. Signiﬁcance after Bonferroni correction was set at
P< 0.0017. Therewas no signiﬁcant effect of genotype on diagnosis.
This result indicated that 5-HTTLPR did not affect DMR.
3.3. Correlations between DMR and total HAM-D scores, and DMR
and total ETISR-SF scores
Next, we examined correlations between the methylation rates
for each CpG unit of the CpG island of the SLC6A4 gene and the
severity of depressive symptoms as well as the number of early
adversities (Table 3). Regarding the severity of MD, there was a
signiﬁcant positive correlation between the methylation rate for
CpG 76 and total HAM-D score (jrj ¼ 0.30, P ¼ 0.03, power ¼ 0.57).
Regarding early adversity, while there was a signiﬁcant negative
correlation between the methylation rate of CpG 3 and total ETISR-
SF score (jrj ¼ 0.32, P ¼ 0.02, power ¼ 0.63), a signiﬁcant positive
correlationwas found between themethylation rate for CpG 76 and
total ETISR-SF score (jrj ¼ 0.32, P ¼ 0.02, power ¼ 0.63).
3.4. DNA methylation proﬁles in the CpG island of the SLC6A4 gene
before and after treatment (unmedicated vs medicated patients)
To evaluate the effect of 6-week antidepressant treatment on
DNA methylation proﬁles in the CpG island of the SLC6A4 gene,
two-way hierarchical clustering analysis was performed
(Supplemental Fig. 3). At any height of the dendrogram acquiredalthy controls and patients with major depression.
Depression (6W) Statistical analysis
Rate (%) (mean  S.E.M) Con vs Dep (P-value) Dep vs D6W (P-value)
7.7  0.5 0.20 0.68
6.1  0.3 0.24 0.0004*
5.7  0.6 0.84 0.03
5.7  0.6 0.84 0.03
25.2  0.8 0.50 0.95
4.6  0.2 0.09 0.08
3.6  0.2 0.79 0.28
6.3  1.3 0.23 0.69
11.8  3.2 0.58 0.17
2.0  0.3 0.69 0.28
4.1  0.2 0.10 0.29
5.5  0.3 0.007 0.94
3.8  0.2 0.21 0.10
8.0  0.6 0.73 0.44
6.5  0.5 0.72 0.13
15.2  0.4 0.24 0.34
1.1  0.3 0.51 0.77
21.5  0.5 0.43 0.23
19.2  1.6 0.59 0.44
21.5  0.5 0.43 0.23
23.8  0.6 0.61 0.67
34.7  2.7 0.92 0.18
13.5  0.4 0.29 0.16
15.6  0.9 0.63 0.99
49.3  2.6 0.56 0.20
16.6  0.7 0.91 0.56
2.8  0.3 0.80 0.50
9.8  0.8 0.14 0.59
34.1  1.0 0.38 0.99
ession6W (D6W); medicated patients with MD.
thMD); Wilcoxon ranked signed test (unmedicated patients withMD andmedicated
as set at P < 0.0017.
Table 3
Relationships of the DNA methylation rates at the CpG island of the SLC6A4 gene
with clinical characteristics in patients with major depression.
Correlation coefﬁcient
HAM-D ETI IR
CpG 1 0.26 0.15 0.08
CpG 3 0.03 0.32* 0.36*
CpG 4 0.02 0.008 0.01
CpG 10 0.02 0.008 0.01
CpG 11 0.24 0.25 0.06
CpG 24,25 0.09 0.08 0.008
CpG 26,27,28 0.17 0.05 0.004
CpG 29 0.11 0.01 0.12
CpG 30 0.16 0.12 0.15
CpG 31,32 0.17 0.09 0.10
CpG 33,34,35,36 0.03 0.14 0.17
CpG 37 0.06 0.04 0.18
CpG 39,40 0.23 0.06 0.11
CpG 41,42 0.21 0.19 0.03
CpG 49,50,51,52 0.07 0.28 0.07
CpG 55 0.13 0.19 0.05
CpG 56 0.26 0.18 0.04
CpG 57,58 0.19 0.03 0.12
CpG 62 0.24 0.10 0.05
CpG 65,66 0.19 0.03 0.12
CpG 67,68 0.15 0.003 0.03
CpG 70 0.15 0.17 0.10
CpG 71,72,73 0.04 0.05 0.14
CpG 74 0.16 0.19 0.13
CpG 75 0.07 0.06 0.23
CpG 76 0.30* 0.32* 0.07
CpG 78 0.03 0.17 0.02
CpG 79 0.21 0.06 0.20
CpG 80,81 0.13 0.11 0.14
ETI: Early Trauma Inventory, IR: improvement ratio, HAM-D: Hamilton Rating Scale
for Depression.
Statistical analysis: Spearman rank correlation test.
The correlations between the methylation rates and total HAM-D scores, total ETI
scores and IR are shown.
The asterisks (*) behind of several correlations indicate signiﬁcantly correlations
which have statistically signiﬁcant P-values in subsequent analyses by t-test.
Signiﬁcance was set at P < 0.05.
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unmedicated patients and medicated patients (Supplemental
Fig. 3). We also compared the methylation rates for each CpG unit
between unmedicated and medicated patients (Table 2). A signiﬁ-
cant difference in the methylation rates for CpG 3 (jZj ¼ 3.47,
P ¼ 0.0004, power ¼ 0.77) was found between unmedicated and
medicated patients.
3.5. Relationship between DMR and improvement ratios in response
to 6-week antidepressant treatment
To evaluate the potential of DMR as a predictor of treatment
response, we analyzed the relationship between pre-treatment
methylation rates for each CpG unit and therapeutic responses.
The therapeutic responses to antidepressants (paroxetine, ﬂuvox-
amine, or milnaciprane) for 6 weeks were deﬁned based on IRs.
Correlation analysis was conducted using the IR and the pre-
treatment methylation rates for each CpG unit. The pre-treatment
methylation rate of CpG 3 showed a signiﬁcant positive correlation
with IRs in MD patients (jrj ¼ 0.36, P ¼ 0.02, power ¼ 0.64, Table 3).
Two-way hierarchical clustering analysis was performed using
samples from patients with an IR of 50% or more, and patients with
an IR of less than 50% (Supplemental Fig. 4). At any height of the
dendrogram acquired from clustering analysis, it was impossible to
classify patients into 2 groups in agreement with the IRs
(Supplemental Fig. 4).
Subsequently, we compared the pre-treatment methylation rate
of CpG 3 between these 2 groups because it was only changedsigniﬁcantly after antidepressant treatment. The pre-treatment
methylation rate of CpG 3 correlated with IRs, and a signiﬁcant
difference was observed (jUj ¼ 1.98, P ¼ 0.047, power ¼ 0.33).
We determined the relationship between IR and the methyl-
ation change of CpG 3 before and after treatment. However, there
was no signiﬁcant correlation (data not shown). Furthermore, we
did not identify a signiﬁcant correlation between IR and ETI (data
not shown).
4. Discussion
In the present study, we could not distinguish between healthy
controls and unmedicated patients with MD, or between unmedi-
cated and medicated patients with MD based on the results of two-
dimensional hierarchical clustering analysis using DNA methyl-
ation rates of CpG units in the CpG island of the SLC6A4 gene. Two-
way hierarchical clustering analysis and two-factor ANOVA using
genotypes (l allele and s/s alleles) and diagnoses (healthy controls
and patients withMD) as ﬁxed factors revealed that 5-HTTLPR itself
did not affect DMR. Comparisons of DNAmethylation rates for each
CpG unit indicated that analysis of the pre-treatment methylation
rate of CpG 3 might be useful for determining the therapeutic re-
sponses to antidepressants. In addition, correlation analysis using
the DNA methylation rate for each CpG unit revealed that DNA
methylation rates of several CpG sites were associated with char-
acteristics of patients with MD: CpG 3 and CpG 76 for early
adversity in MD patients, and CpG 76 for severity of MD symptoms.
We also analyzed the datawith respect to the therapeutic response.
Although we could not distinguish between patients with high and
low therapeutic responses by clustering analysis using all the DNA
methylation rates, correlation analysis revealed the pre-treatment
DNA methylation rate of CpG 3 correlated with the therapeutic
response and an individual comparison of CpG 3 revealed that the
DNA methylation rate of CpG 3 was signiﬁcantly different.
Many epigenetic changes are reversible in response to both
external and internal stimuli, indicating a mechanism for in-
teractions of the genome with the environment. Notably, various
factors associated with complex diseases, for example nutrition,
chemical exposure, and psychosocial stress, have been correlated
with epigenetic changes, particularly DNA methylation (Feil and
Fraga, 2011). Such ﬁndings integrate epigenetic research with
population-based epidemiological research investigating not only
diagnosis methods (Mill and Heijmans, 2013), but also drug re-
sponses and the effect of therapeutic drugs (Duarte, 2013). We
recently reported that classiﬁcation based on DNA methylation
proﬁles of the CpG island in the promoter of exon I of the BDNF
gene could be a valuable diagnostic biomarker for MD (Fuchikami
et al., 2011). In addition, D’Addario et al. (2013) reported the
possible association of changes in DNA methylation of the BDNF
promoter with the onset of and/or susceptibility to bipolar disorder,
or with mood-stabilizing compounds and antidepressants. In
contrast with results of two previous studies, the present study
suggested possible associations of DNA methylation of the SLC6A4
gene with the diagnosis of MD, antidepressant treatment, early
adversity, and therapeutic responses only when analyses based on
data for each speciﬁc CpG unit were used, but not when using
analyses of all DMR.
In general, an association between DNA methylation and tran-
scriptional activity is considered an important marker of functional
relevance (Stranger et al., 2007; Dimas et al., 2009).
With regard to the SLC6A4 gene, Philibert and colleagues re-
ported a signiﬁcant association between SLC6A4 promoter
methylation levels and mRNA levels using peripheral blood from
patients with depression (Philibert et al., 2007). However, it is
becoming evident that the relationship between DNA methylation
S. Okada et al. / Journal of Psychiatric Research 53 (2014) 47e5352and gene expression is not always tightly linked. In terms of
biomarker identiﬁcation, the fact that methylation is closely asso-
ciated with a speciﬁc pathological condition is thought to be
important, even if methylation does not induce gene silencing
(Ushijima, 2005). 5-HTT is associated with pathological conditions
and the treatment of MD (Lesch and Gutknecht, 2005; Murphy
et al., 2008). In this context, the present study only analyzed DNA
methylation but not gene expression levels. Future studies exam-
ining DNA methylation in the promoter of the SLC6A4 gene
together with gene expression will be needed to reveal the func-
tional relevance of DNA methylation of this gene in the patho-
physiology of MD.
Thus, although the biological signiﬁcance of changes in DNA
methylation rates for speciﬁc CpG units of the SLC6A4 gene is not
known, the results of the present study suggest that such infor-
mation may provide important clinical information regarding MD.
Previous reports described the possibility of a joint effect of 5-
HTT methylation and 5-HTTLPR s allele carriage on the risk for
depression (Olsson et al., 2010) and the effect of CpG islands on
DNA methylation by distantly-located SNPs in a fraction of genes
(Bell et al., 2011; Soto-Ramirez et al., 2013). Therefore, we evaluated
the inﬂuence of the 5-HTTLPR allele on DMR. Contrary to the results
of Olsson et al. (2010), we found no signiﬁcant effect on the DNA
methylation rates of any CpG unit by genotype. The discrepancy
between these studies may be attributed to differences in the tis-
sues (buccal cells vs blood cells) and analytic methods used (Olsson
divided the CpG island of the SLC6A4 gene into sub-regions ac-
cording to co-variation in methylation levels between CpG units).
Changes in the DNA methylation rate of CpG 3 were the most
intriguing ﬁnding of this study. The DNA methylation rate of CpG 3
correlated negatively with ETISR-SF, and was signiﬁcantly changed
after antidepressant treatment, but correlated positively with
therapeutic responses. Several studies have reported that increased
DNA methylation of several CpG units within the SLC6A4 gene was
associated with early adversity (Ouellet-Morin et al., 2013) and
antidepressant treatment (Kang et al., 2013). Although those
studies investigated different and smaller regions of the SLC6A4
gene for DNA methylation analyses compared with the present
study, they suggested the versatility of DNA methylation of speciﬁc
CpG units of the SLC6A4 gene induced by environmental factors. In
addition, the high prevalence of early adversity in treatment-
resistant depressed patients was reported recently (Tunnard
et al., 2013). Although the function of CpG 3 methylation of the
SLC6A4 gene is unknown, the sequence of changes in the methyl-
ation rates at this region (negative correlation with early adversity
and positive correlation with response rates) indicates the possible
involvement of this factor in the mechanism of resistance to anti-
depressant treatment.
In summary, analyses using DNA methylation rates for speciﬁc
CpG units of the SLC6A4 gene, but not analyses based on DNA
methylation rates of all CpG units, may be a potential biomarker for
the diagnosis, severity of symptoms, early adversity, and history of
antidepressant treatment in patients with MD. Notably, the pre-
treatment DNA methylation rate for CpG 3 may be associated
with antidepressant treatment responses. In addition, the DNA
methylation rate for CpG 3 indicated possible involvement in the
mechanism of treatment resistance associated with early adversity.
Further studies examining the function of these CpG units will help
to establish more sophisticated methods for the diagnosis and
treatment of MD.
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